S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NYSE:BHVN

Biohaven Pharmaceutical Stock Forecast, Price & News

$84.03
+6.16 (+7.91 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$77.00
Now: $84.03
$84.33
50-Day Range
$76.04
MA: $83.92
$91.75
52-Week Range
$26.56
Now: $84.03
$100.77
Volume921,024 shs
Average Volume596,935 shs
Market Capitalization$5.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.09
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.
Biohaven Pharmaceutical logo

Headlines

Recap: Biohaven Pharmaceutical Q4 Earnings
March 1, 2021 |  finance.yahoo.com
Biohaven To Report Fourth Quarter And Full Year...
February 23, 2021 |  benzinga.com
Biohaven Provides Update On ESG Practices
February 8, 2021 |  finance.yahoo.com
Notable Tuesday Option Activity: BHVN, CMG, IRBT
January 19, 2021 |  nasdaq.com
BHVN Feb 2021 130.000 call
January 17, 2021 |  au.finance.yahoo.com
BHVN Feb 2021 45.000 put
January 17, 2021 |  au.finance.yahoo.com
BHVN Jan 2021 105.000 put
December 23, 2020 |  au.finance.yahoo.com
BHVN Jan 2021 130.000 call
December 21, 2020 |  au.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:BHVN
CUSIPN/A
Phone203-404-0410
Employees647
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.14) per share

Profitability

Net Income$-528,800,000.00

Miscellaneous

Market Cap$5.04 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.79 out of 5 stars

Medical Sector

169th out of 1,972 stocks

Pharmaceutical Preparations Industry

75th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
$84.03
+6.16 (+7.91 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BHVN News and Ratings via Email

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions

Is Biohaven Pharmaceutical a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Biohaven Pharmaceutical stock.
View analyst ratings for Biohaven Pharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than Biohaven Pharmaceutical?

Wall Street analysts have given Biohaven Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biohaven Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Biohaven Pharmaceutical's next earnings date?

Biohaven Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Biohaven Pharmaceutical
.

How were Biohaven Pharmaceutical's earnings last quarter?

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) posted its earnings results on Sunday, February, 28th. The company reported ($3.62) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.89) by $0.73. The company had revenue of $35.10 million for the quarter, compared to the consensus estimate of $35.01 million. The company's quarterly revenue was up 350900.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($2.85) EPS.
View Biohaven Pharmaceutical's earnings history
.

How has Biohaven Pharmaceutical's stock been impacted by Coronavirus?

Biohaven Pharmaceutical's stock was trading at $39.46 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BHVN stock has increased by 112.9% and is now trading at $84.03.
View which stocks have been most impacted by COVID-19
.

What guidance has Biohaven Pharmaceutical issued on next quarter's earnings?

Biohaven Pharmaceutical issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $35-35 million, compared to the consensus revenue estimate of $25.31 million.

What price target have analysts set for BHVN?

11 analysts have issued 12-month price objectives for Biohaven Pharmaceutical's shares. Their forecasts range from $41.00 to $120.00. On average, they expect Biohaven Pharmaceutical's stock price to reach $95.30 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price.
View analysts' price targets for Biohaven Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are Biohaven Pharmaceutical's key executives?

Biohaven Pharmaceutical's management team includes the following people:
  • Dr. Vladimir Coric, CEO & Director (Age 50, Pay $1.14M)
  • Mr. James Engelhart, Chief Financial Officer & Treasurer (Age 57, Pay $656.39k)
  • Ms. Kimberly Gentile, Sr. VP of Clinical Operations (Age 55, Pay $614.09k)
  • Dr. Elyse Stock M.D., Chief Medical Officer (Age 63, Pay $594.39k)
  • Mr. William Jones M.B.A., Chief Commercial Officer of Migraine & Common Diseases (Age 57, Pay $1.3M)
  • Mr. Clifford Bechtold, Chief Operating Officer
  • Mr. Matthew DeLawder, Director of Accounting
  • Dr. Charles Conway, Chief Scientific Officer (Age 59)
  • Ms. Wendy Goss, Exec. Admin. Assistant
  • Ms. Jenny Strauss M.P.H., Mang. of Medical Information & Communication

Who are some of Biohaven Pharmaceutical's key competitors?

What other stocks do shareholders of Biohaven Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven Pharmaceutical IPO?

(BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven Pharmaceutical's stock symbol?

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Who are Biohaven Pharmaceutical's major shareholders?

Biohaven Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.88%), Stifel Financial Corp (4.24%), Alliancebernstein L.P. (2.01%), Wells Fargo & Company MN (1.67%), Brown Advisory Inc. (1.48%) and Bank of New York Mellon Corp (1.35%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Kimberly Gentile, Robert Berman, Vlad Coric and William A Jones Jr.
View institutional ownership trends for Biohaven Pharmaceutical
.

Which major investors are selling Biohaven Pharmaceutical stock?

BHVN stock was sold by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Alliancebernstein L.P., Columbus Circle Investors, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Candriam Luxembourg S.C.A., Rhenman & Partners Asset Management AB, and Wells Fargo & Company MN. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Kimberly Gentile, Robert Berman, and William A Jones Jr.
View insider buying and selling activity for Biohaven Pharmaceutical
or view top insider-selling stocks.

Which major investors are buying Biohaven Pharmaceutical stock?

BHVN stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Clearbridge Investments LLC, Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Morgan Stanley, BlackRock Inc., International Biotechnology Trust PLC, and Brown Advisory Inc.. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs, and Vlad Coric.
View insider buying and selling activity for Biohaven Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Biohaven Pharmaceutical?

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven Pharmaceutical's stock price today?

One share of BHVN stock can currently be purchased for approximately $84.03.

How much money does Biohaven Pharmaceutical make?

Biohaven Pharmaceutical has a market capitalization of $5.04 billion. The company earns $-528,800,000.00 in net income (profit) each year or ($10.91) on an earnings per share basis.

How many employees does Biohaven Pharmaceutical have?

Biohaven Pharmaceutical employs 647 workers across the globe.

What is Biohaven Pharmaceutical's official website?

The official website for Biohaven Pharmaceutical is www.biohavenpharma.com.

Where are Biohaven Pharmaceutical's headquarters?

Biohaven Pharmaceutical is headquartered at 215 CHURCH STREET, NEW HAVEN CT, 06510.

How can I contact Biohaven Pharmaceutical?

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.